SFDA official: Nader program streamlines access to rare disease treatments
The Nader program offers regulatory incentives to accelerate access to rare disease therapies, supporting researchers and pharmaceutical developers, an SFDA official said.
Nawaf Al-Mutairi, Head of Standards Development at the Saudi Food and Drug Authority (SFDA), explained that the Nader program aims to expedite access to rare disease therapies. The program offers regulatory incentives to support researchers and pharmaceutical developers. Speaking to Al Ekhbariya TV, Al-Mutairi emphasized that these measures are specifically tailored to the unique requirements of rare diseases while upholding the essential standards of quality, safety, and efficacy in the medicines.
The SFDA introduced the Nader program as part of its regulatory strategy for rare disease medicines, with the goal of fostering the creation and approval of pharmaceutical products designed to address rare diseases.
Written by urgent.news from Ajel English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
